The role of carnitine in myocardial dysfunction

Area of Science:

• Cardiology
• Biochemistry
• Nephrology

Background:

• Cardiac disease is a leading cause of mortality in end-stage renal disease (ESRD) patients.
• Dialysis patients often develop carnitine deficiency.
• L-Carnitine (carnitine) exhibits cardioprotective effects against hypoxia and oxidative stress.

Purpose of the Study:

• To evaluate the role of L-carnitine in managing cardiac disorders.
• To assess the impact of carnitine supplementation on post-myocardial infarction (MI) patients.
• To investigate carnitine's benefits in the dialysis population with cardiac conditions.

Main Methods:

• Systematic review of studies on carnitine administration in cardiac patients.
• Analysis of short-term (1-3 months) and long-term (up to 1 year) treatment effects.
• Focus on cardiac parameters, mortality, heart failure, angina, exercise tolerance, and oxygen consumption.

Main Results:

• Carnitine treatment (1.5-6 g/d) post-MI is associated with reduced mortality and heart failure.
• Carnitine use led to smaller increases in left ventricular volumes compared to placebo.
• Short-term therapy improved heart failure symptoms and angina post-MI.
• Carnitine enhanced exercise tolerance and oxygen consumption in heart failure patients.
• Studies in dialysis patients suggest beneficial effects on cardiac parameters.

Conclusions:

• L-Carnitine demonstrates potential as a therapeutic agent for various cardiac disorders, including post-MI and heart failure.
• Carnitine supplementation may be particularly relevant for dialysis patients due to common carnitine deficiency and high cardiac mortality.
• Further long-term studies are warranted to confirm these findings, especially in the ESRD population.